Vasoactive Intestinal Peptide for the treatment of Female Sexual Arousal Disorder
Award amount
$225,000Program and phase
SBIR · Phase IAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- PHARMAIN CORPORATION
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- G1NAHNEAVKK9
- Solicitation number
- PA13-088
- Topic code
- NIA
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Subcutaneous Drug Development for Portal Hypertension Ascites
- Development of an immunomodulating peptide as a therapy for osteosarcoma in canine and human
- CMC of Peptide Formulation for the Treatment of ARDS
- CMC of Peptide Formulation for the Treatment of ARDS
- Subcutaneous Drug Development for Portal Hypertension Ascites
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Evaluate the Safety, Tolerability, and Immunogenicity of Adjuvanted Preventive Dual Aβ/tau Vaccine, Duvax in Healthy Volunteers
- A Drug Discovery Platform to Prioritize Development of Natural Product Neuromodulators for Treating Cognitive Impairment
- VR-CARES: Feasibility of Virtual Reality for Caregiver Assembly, Relief, Empowerment, and Support to improve social connection, health, and at-home dementia care
- Developing an Integrated Brain State Monitor for Personalized Anesthesia Decision Support: Preventing Postoperative Delirium in Elderly and Patients At Risk for Alzheimer's or Related Dementias
- Lead Optimization of a Therapeutic Candidate for Alzheimer’s Disease
Research funding history
21 SBIR/STTR records share this UEI (2004–2024). Reported award amounts total $21,739,117. Reported amounts are not federal obligations.
Phases: Phase I, Phase II, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services